International registry on the use of the CytoSorb ® adsorber in ICU patients
Extracorporeal blood purification techniques have been used for treating critically ill patients for more than 15 years. This approach is based on current evidence that an excessive inflammatory host response which is accompanied by a continuous release of inflammatory mediators may contribute to multiple organ failure and finally death. Cytotoxic effects with substrate loss in several organs [1] and immune paralysis [2] resulting in an increased susceptibility to secondary infections characterize the consequences of an uncontrolled release of inflammatory mediators. This led to the view that elim-inating inflammatory mediators, bacterial toxins, and tissue degradation proteins from the systemic circulation might restore immunoreactivity and positively affect outcomes. Several mechanisms of action are supposed to account for the efficacy [3] [4] [5] and many approaches of extracorporeal blood purification techniques (hemofiltration, hemadsorption, plasmapheresis, etc.) have been investigated [6] . By recording physiological parameters and surrogate markers, many studies have shown that these approaches are efficient and well tolerated. However, questions surrounding the appro- priate application, timing, duration, and frequency remain to be elucidated. In addition, studies with a higher number of patients should assess efficacy by recording clinically relevant study endpoints (mortality, organ dysfunction).
Clinically established methods differ in several aspects, such as the spectrum of retainable pathogenic molecules (e. g., cytokines and/or endotoxins), loss and need for supplementation of physiological blood components (low molecular substances, albumin, antibiotics), use-related technical and staff effort, and product costs.
Several medical devices that are based on the principle of hemadsorption methods are in different phases of clinical development [7] . The active component of the approved Toraymyxin (Toray Industries, Japan) is polymyxin B, an antibiotic that is immobilized on polystyrene fibers. The active ingredient enables the extraction of endotoxins. Its use is associated with high costs. Another product, which adsorbs the endotoxin LPS (Alteco Medical, Sweden), has failed to show convincing results in clinical testing. The product OXiris (Gambro-Hospal, France) is being clinically tested. It contains a biopolymer that is able to eliminate endotoxins and cytokines. The MATISSE system (Fresenius, Germany) relies on the adsorption qualities of human albumin which is immobilized on polystyrene. However, clinical results remain unconvincing. The nonspecific adsorption of cytokines (but not endotoxins) on a synthetic resin module with subsequent hemofiltration is used in the product of the Italian manufacturer Bellco. Efficacy in septic patients is currently being tested.
The approved product CytoSorb ® (CytoSorbents, USA) contains a biocompatible polystyrene and divinylben- zene copolymer as a sorbent. The agent eliminates inflammatory cytokines and metabolic products in a quick and reliable way, but cannot adsorb endotoxins. Its efficient and safe use in patients with septic shock was proven in a randomized clinical multicenter study (NCT 00359130).
Another study that recently started investigates the adsorber's use in elective cardiopulmonary surgical interventions. As the product is compatible with other methods of extracorporeal blood purification (renal replacement therapy, cardiopulmonary bypass), an above-average usage in clinical practice is very likely, and the medical community has signaled significant interest [8] .
Objectives and design
The aim of this registry is to record the use of CytoSorb ® under real-life conditions in as many cases as possible. All CytoSorb ® applications in different clinical settings and in all patients who are treated with this technology are expected to be documented. The objectives of the registry are collection of real-life data on a broad scale, centralized, structured and comprehensive documentation, and controlled data exchange. The information gathered will be used to augment the knowledge on the clinical efficacy of the technology, to optimize the quality of its therapeutic application, and to identify and promptly handle possible complications related to the use of CytoSorb ® . The registry will record relevant information in the course of product use, e. g., diagnosis, comorbidities, course of the condition, treatment, concomitant medication, and clinical laboratory parameters. An active form of data collection where data is prospectively collected by qualified staff is particularly suited for this purpose [9] . Registry data might help close knowledge gaps and open practical issues. Due to the patient group's heterogeneity, the registry can identify subgroups, assess their risk-benefit profile and examine their safety profile. Registry data are essential for assessing a therapy's significance within the healthcare landscape [10] . Institutions that contribute data to the registry benefit in several ways: ). However interleukin-6 levels were markedly reduced after treatment (median 5000 pg/ml before and 289 pg/ml after treatment, respectively). Conclusions. This third interim report demonstrates the feasibility of the registry with excellent data quality and completeness from 20 study centers. The results must be interpreted with caution, since the numbers are still small; however the disease severity is remarkably high and suggests that adsorber treatment might be used as an ultimate treatment in life-threatening situations. There were no device-associated side effects. 
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Zytokine · Extrakorporale lebenserhaltende Maßnahmen · Entzündung · Sepsis · Intensivstationen they will obtain continuous retrospective feedback of their own results, their data will be periodically compared with data from other participating sites, and they will have access to regularly published analyses of the results. On the basis of these data, they can optimize their use of CytoSorb ® [11] .
Study population
All medical institutions thatuse CytoSorb ® are eligible for participation. At inception, data collection was planned for a period of 3 years. An extension of the registry duration beyond that period is possible. The expected sample is around 1000 patients/year. Inclusion criteria are depicted in . Table 1 . There are no exclusion criteria.
Patients with sepsis and septic shock
Patients with sepsis/septic shock are enrolled according to the afore mentioned criteria ("Criteria defining sepsis and septic shock" in Supplementary material). 1 • Site registration on website www.cytosorb-registry.org 2 • Start package sent by ZKS (cooperation contract, ethics committee votes) 3 • Site ready for data collection 4 • Patient recruitment by site 5 • Data collection by site Fig. 1 9 Requirements before data collection by site
Patients undergoing cardiac surgery with CPB
This population includes patients who undergo cardiac surgery with the use of cardiopulmonary bypass (CPB). The most frequent cardiac interventions associated with CPB use include coronary artery bypass surgery, heart valves replacement surgery, and surgery of the major vessels.
Two possible variants for using the CytoSorb ® device are envisaged, (1) preemptive use aiming to reduce circulating inflammatory cytokines immediately before and during surgery in risk patients;
(2) postoperative use during the stay in ICU.
Other patients
Other patients are any other patients who are treated with the CytoSorb ® device and who are not included in the sepsis/septic shock or cardiac surgery groups. The shortlist of indications includes, but is not restricted to: liver failure, acute pancreatitis, severe trauma, extensive burns, acute respiratory failure.
Data documentation
Data is recorded by assigned staff from the participating centers. Table 2 and "Flowcharts and data content in the eCRF" in Supplementary material, respectively.
Data management
Data capture takes place via a web application on the servers of the Center for Clinical Studies at Jena University Hospital with OpenClinica ® , a study management software. OpenClinica meets all regulatory requirements (GCP, 21CFRPart11). It has an integrated audit trail that records any kind of data changes automatically. This data recording cannot be modified by the users. In order to ensure a pseudonymized analysis of data, each patient data set is given a unique patient identification number when being entered into the study database. Data management is done by using the study management software OpenClinica ® . Prior to its application, the study database is checked for errors (and corrected if necessary) by the database programmer and staff involved (e. g., biometricians, study investigator, study nurse). Only then is the database declared ready for use. Data is recorded in the study database via an encrypted data link (HTTPS) by use of data entry masks. While being entered, the data is already being checked for completeness and correctness. Missing or obviously erroneous values produce immediate error messages that require changes from the data inputting person. Correctness of data is verified by further range, validity, and consistency checks. The data collecting centers are contacted if data is not plausible or missing (query management) so that corrections/completions can be made. Any modification of the data-e. g. because of incorporation of query answers-is documented in the database by an audit trail. By applying a hierarchical, role-based access control, unauthorized access to patient data is impossible. Staff is informed about their obligation of nondisclosure of access codes. There is a daily backup of all data.
Each center has to complete a hospital/ICU questionnaire, and for each patient a questionnaire has to be filled in.
Recording adverse effects
The CytoSorb ® registry is noninterventional observational data collection. Advice on treatment is not provided by the registry. Obligations to notify the authorities about adverse effects in clinical studies do not apply. There is no systematic recordingofadverse effectsinthe registry. However, one objective of the registry is to record complications or effects that occurred while using CytoSorb ® . Complications have to be recorded in the eCRF.
Implementation of the project
Potential participating centers are approached by the steering committee and via information that is delivered together with the CytoSorb ® adsorber. In cases where a hospital is interested in participation, a questionnaire on the hospital's characteristics needs to be completed (. Fig. 1) . After receipt of this information, an account in the registry is created. A contract regulating rights and obligations is mandatory. Data collecting staff of participating centers is trained by the responsible CytoSorb Registry project manager at the Center for Clinical Studies in Jena. The physicians in charge of the registry are responsible for on-site dissemination of knowledge in their centers. 
Data analysis
The primary endpoint is observed in-hospital mortality, compared to the mortality predicted by the APACHE II and SAPS II scores, respectively [12, 13] . Survival rates are compared by use of a logistic regression model according to Knaus et al. [12] . Significance level is preset at α = 0.05. If a difference is verifiable, a binominal test will be performed for the score groups 0-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, and ≥35. The significance level for the binominal tests will be adjusted by use of the Bonferroni-Holm correction in a mode that a total level of α = 0.05 is preserved. Major secondary endpoint is the change of the SOFA scores (ΔSOFA). For this, the difference between SOFA scores of Exam 1 (within 24 h before CytoSorb ® use) and Exam 2 (24 h after CytoSorb ® use) are calculated.
ΔSOFA is analyzed by using T-test. Further secondary endpoints are depicted in . Table 3 . In addition, an aggregated description of treatment-related complications (frequency per organ/system) and an assessment of the treatment success (descriptive, frequency analysis) are used for assessing the safety of CytoSorb ® use. In patients with preemptive CytoSorb ® application the survival analysis will be performed using the EURO score [14] .
Calculation of sample size: the feasibility analysis indicated an expected number of 1000 patients per year. Based 
Publication of results/registration of the data collection
The CytoSorb ® registry is registered in the study registries ClinicalTrials.gov and the German Registry for Clinical Studies Freiburg (DRKS). Use of data from the CytoSorb ® registry by participating centers and external parties is regulated by a data use agreement. Reports on the semiannual analyses and a retrospective access to their own data will be provided for all participating centers. Publication of results generated from registry data are subject to separate publication regulations and are coordinated by the steering committee.
Ethical principles and patient safety
The registry represents merely a collection of data on the use of CytoSorb ® in accordance with the prescribing information. Therefore, there are no ethical objections concerning patients and patient safety. The decision of the attending physician is the sole factor which determines the assignment of a patient to treatment with CytoSorb ® , and the physician's participation in the registry does not influence his decision. Patient information about the device is provided and signing of informed consent is an es-sential precondition for participation in the registry. In case patients are unable to consent because of critical illness, local practice for collecting data on these patients has to be applied. This study protocol has been submitted to the Institutional Review Board (IRB) of the Faculty of Medicine at Friedrich Schiller University, Jena that acts as the IRB in charge for Germany. All German ethic committees involved are informed about the participation of centers in their area of responsibility and the decision of the IRB in charge. In centers from outside Germany, approval of the local ethics commission in charge is obtained and all national regulations are adhered to.
Data protection
Data collection takes place in the participating centers. All collected medical data are entered by assigned staff of the centers into a computer-based online data entry system and immediately transferred to the documentation center at ZKS Jena. Informed consent on data collection and use is obtained prior to inclusion of the patient or at the earliest possible time. Due to the seriousness of the medical condition, it has to be assumed that most patients are unable to consent. Thus, oral or written informed consent prior to the data collection cannot be obtained. In this case, the data collecting institutions have to observe their locally established way of proceeding for including patients incapable of giving informed consent. The patient's consent is recorded in the patient file. Patients or their legal representatives have the right to withdraw their consent and to inter-rupt participation in the study at any time and without giving reasons. In this case, the patient's data will be deleted. Data collection occurs upon early stage pseudonymization of the patients. Participating centers draw up local patient identification lists and allocate a unique multidigit number to each patient. Only pseudonymized patientrelated medical data are transferred from the participating center to the documentation center; no information that allows identification of patients is revealed to the documentation center.
For answering queries that might arise while checking the data quality and plausibility, the data collecting center is able to trace back the pseudonym to the patient for a given period of time. The patient identification list remains at the data collecting center and can be accessed by a limited group of staff members (principal investigators).
The patient identification list has to be kept locked up for at least 10 years in the data collecting center. The local principal investigator is responsible for this. The sponsor has to authorize the destruction of the patient identification list.
Owners of the registry data are the steering committee members. The Center for Clinical Studies at Jena University Hospital is appointed as the documentation center, also in charge of data processing. Backup of data is done regularly. The data storage devices are stored in a locked, central room, accessible only by the system administrator. Only the following persons have access to the data: staff of the ZKS that are directly involved in the project (statisticians, data manager, IT coordinator). Analyses are carried out by statisticians of ZKS Jena.
Publication of the data takes place in an aggregated form only. Information about individual patients, ICUs or hospitals will not be published or shared.
All data collecting centers can request access to the data they contributed. Requests for data submitted by external interested parties are decided on by the steering committee. Again, disclosure of data takes place in an aggregated form only. 
Data protection statement
Data entry is done in the data collecting centers. Data processing and analysis takes place at the Center for Clinical Studies at Jena University Hospital. Regulations of the data protection acts of all countries concerned are satisfied. Access to the study data is limited to registry staff. These persons are bound to secrecy. Data are protected from unauthorized access.
Sponsor and funding
For the success of a registry, close cooperation between users, product suppliers, and sponsors is crucial. Of particular importance is also the scientific editing of knowledge generated from the registry and the communication of results to all stakeholders. Jena University Hospital, represented by Prof. Dr. F. M. Brunkhorst, is the scientific institution that runs this registry. The steering committee sup-ports the implementation of the registry.
The CytoSorb ® registry is funded by Cy-toSorbents Europe GmbH. The Center for Clinical Studies at Jena University Hospital is able to provide all necessary services in the field of data management and project management.
Results from the 3 rd interim report
As of January 30, 2017, 130 centers from 22 countries were participating in the registry (. Figs. 2 and 3) . Data available from the start of the registry on May 18, 2015 to November 24, 2016 were analyzed. Atthis time point, 122 centers from 22 countries participated in the registry, of which 20 centers from four countries provided data from a total of 198 patients (. Fig. 4) . Baseline data was available in 191 patients, treatment phase data in 195 patients and follow-up-data in 193 patients.
Baseline characteristics
One hundred and thirty five (68.2%) patients were male. Mean age was 60.3 ± 15.1 (min-max 21-92) years. Patients with preemptive CytoSorb use in cardiac surgery and other indications were slightly younger (58.6 ± 13.6 and 53.2 ± 17.8, respectively) than patients with sepsis (61.5 ± 14.1), whereas patients with postoperative use in cardiac surgery were slightly older (67.2 ± 12.2). There were no relevant differences between the indication groups in body weight and body height. The majority of patients were admitted for nonsurgical emergency reasons (91 [46.0%]), surgical emergency for 70 (35.4%) and elective surgical for 37 (18.7%) of the patients (. Table 4 ). 
Outcome
Sepsis group
Patients with sepsis were predominantly medical patients (71/135) and exhibited an extreme high risk of death when CytoSorb treatment was initiated (mean APACHE II score in 107/135 patients: 33.1 ± 8.4 [range 15-52]). This is substantial higher than in other sepsis trials, where mean APACHE II scores are usu-ally between 20 and 25 (for instance in the MAXSEP and VISEP trials with 20.2 and 21.6 points and 28-day mortality rates of 22.9 and 25.4%, respectively). The predicted risk of death in the CytoSorb group would be around 78%, whereas the observed mortality was 65%.
This result in the sepsis group is supported by the high SAPS II scores (74.3 ± 16.8 [29-107]), with a predicted mortality of around 81%. The mean SOFA scores were also markedly elevated (17.3 ± 3.99 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ). Substantially lower SOFA scores were observed in for instance the VISEP and MAXSEP trials (7.7 [7.3; 8.2] points). There were no significant decreases in the SOFA scores after treatment (17.2 ± 4.8 ). However, IL-6 levels were markedly reduced after treatment (median 5000 pg/ml before treatment and 289 pg/ml after treatment).
Treating physicians rated the condition as very much/much improved in 45%, as minimally improved in 18%, and as unchanged in 29%. Two patients (1.5%) were rated as much worse or very much worse.
Cardiac surgery with CPB, postoperative
Patients postoperatively treated following cardiac surgery with CPB had a mean APACHE II score of 22.1 ± 7.3 (16/17 patients), with a predicted mortality of 31%, and an observed mortality of 29%. Treating physicians rated the condition as very much/much improved in 53%, as minimally improved in 29%, and as no change in 12%.
Other indications
Patients treated in other indications had a mean APACHE II score of 25.5 ± 8.9 (26/38 patients) with a predicted mortality of 54% and an observed mortality of 32%.
Treating physicians rated the condition as very much/much improved in 58%, as minimally improved in 13%, as no change in 10%, and as minimally worse in 3%.
Summary and Interpretation
This third interim report demonstrates the feasibility of the registry with excel-lent data quality and completeness from twenty study centers. The results must be interpreted with caution, since the numbers are still small; however disease severity is remarkably high and suggests that the adsorber treatment might be used as an ultimate treatment in life-threatening situations. The observed mortality is lower than predicted, but the numbers are too small to draw conclusions. There were no device-associated side effects. However, the duration of treatment with a single adsorber was relatively pronounced, and blood flow rate was low, factors which might be improved in order to increase the clinical efficacy of the device.
